Columvi (glofitamab-gxbm) — Medica
Primary effusion lymphoma
Initial criteria
- age ≥ 18 years
- patient has received one or more lines of systemic therapy
- patient has or will receive pretreatment with Gazyva (obinutuzumab intravenous infusion) before the first dose of Columvi
- medication is prescribed by or in consultation with an oncologist
Approval duration
1 year